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Endocrine tumours predominantly arise sporadically in the general
population, but sometimes occur as part of inherited endocrine
neoplasia syndromes. Multiple endocrine neoplasia type 1 (MEN
1) is an autosomal dominant disorder characterized primarily by
hyperplasia and/or neoplasia of the parathyroid glands, anterior
pituitary and endocrine pancreas. The MEN1 gene is a tumour
suppressor gene located at chromosome band 11q13 (Larsson
et al, 1988) and was recently identified by positional cloning
(Chandrasekharappa et al, 1997).
As well as its involvement in familial MEN 1 and related
syndromes, the MEN1 locus has also been implicated in the
development of MEN 1-type sporadic endocrine tumours. Loss of
heterozygosity (LOH) of markers flanking the MEN1 gene has
been reported in sporadic primary parathyroid lesions (Tahara
et al, 1996; Farnebo et al, 1997a), pancreatic tumours (Teh et al,
1990; Debelenko et al, 1997a), and anterior pituitary tumours
(Bates et al, 1997; Dong et al, 1997), as well as in sporadic cases of
tumours less commonly associated with MEN 1, such as lung,
thymic and gastric carcinoids (Jakobovitz et al, 1996; Debelenko
et al, 1997b), lipomas (Dong et al, 1997) and cutaneous tumours
(Pack et al, 1997). Mutations in the MEN1 gene have been
detected in all of these tumour types (Heppner et al, 1997;
Debelenko et al, 1997c; Zhuang et al, 1997a; Zhuang et al, 1997b;
Böni et al, 1998; Vortmeyer et al, 1998).
This study aims to continue investigations into the role of the
MEN1 gene in sporadic endocrine tumorigenesis, by screening for
LOH of 11q13 markers and mutations in the MEN1 gene in a
series of sporadic tumours of the pancreas, pituitary and parathy-
roids. In addition, we aim to investigate the role of the MEN1 locus
in the development of parathyroid lesions that have arisen secon-
darily due to hypercalcaemia following renal transplantation.
MATERIALS AND METHODS
Patients and tumours
After obtaining informed consent, endocrine lesions from 33
patients undergoing surgery to remove pancreatic (n = 3), anterior
pituitary (n = 8) or parathyroid lesions (n = 22) at the Royal
Brisbane or Princess Alexandra Hospitals in Brisbane were
included in the study. A peripheral blood sample for germline
DNA analysis was also acquired from each patient, for which they
gave informed consent. Diagnosis of primary hyperparathyroidism
was based on the following criteria: elevated serum calcium
(>2.6 mmol/l) and/or serum parathyroid hormone (>5.5 µ mol/l);
and presence of hyperplasia or adenoma following histological
analysis of frozen sections of parathyroid tissue. Usually only one
of the four parathyroid glands was affected in these patients.
Secondary hyperparathyroidism arising in patients with chronic
(or end stage) renal failure is associated with hyperplasia of all
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Summary Endocrine tumours of the pancreas, anterior pituitary or parathyroids arise either sporadically in the general population, or as a part
of inherited syndromes such as multiple endocrine neoplasia type 1 (MEN 1). The mechanisms responsible for the development of sporadic
endocrine lesions are not well understood, although loss of heterozygosity (LOH) of the MEN1 locus on chromosome 11q13 and somatic
mutation of the MEN1 gene have been frequently associated with the development of MEN 1-type sporadic endocrine lesions. To further
investigate the role of the MEN1 gene in sporadic endocrine tumorigenesis, we analysed DNA from 14 primary parathyroid lesions, 8 anterior
pituitary tumours and 3 pancreatic tumours for the presence of somatic MEN1 gene mutations and LOH of seven microsatellite markers
flanking the MEN1 locus. In addition, we similarly analysed 8 secondary parathyroid lesions which arose in patients with chronic renal failure.
None of the patients studied had a family history of MEN 1. Three primary parathyroid lesions and one pancreatic tumour (glucagonoma)
were found to have lost one allele at the MEN1 locus. Somatic mutations were identified by SSCP and sequence analysis in one of these
parathyroid lesions (P320L) and in the glucagonoma (E179V). These results support previous findings that inactivation of the MEN1 tumour
suppressor gene contributes to the development of sporadic MEN 1-type endocrine lesions but is not associated with the development of
parathyroid hyperplasia seen in some renal failure patients. © 2000 Cancer Research Campaign
Keywords: MEN 1; LOH; mutation analysis; endocrine tumour; sporadic
1003
Received 23 August 1999
Revised 2 May 2000
Accepted 15 June 2000
Correspondence to: N Hayward
British Journal of Cancer (2000) 83(8), 1003–1008
© 2000 Cancer Research Campaign
doi: 10.1054/ bjoc.2000.1385, available online at http://www.idealibrary.com on four parathyroid glands. A diagnosis of secondary hyperpara-
thyroidism was made in 8 patients, 6 of whom also underwent
(successful) renal transplants. In general, any hyperplastic material
remaining after diagnostic histopathological studies was analysed.
A diagnosis of glucagonoma was made in a patient with elevated
fasting plasma glucagon levels (>100 ng/l) and positive staining
for glucagon in an islet cell tumour. One case of insulinoma was
diagnosed in a hypoglycaemic patient with an insulin-positive islet
cell tumour. Pituitary tumours were classified as growth hormone-
or prolactin-producing according to clinical evidence of hormone
excess, and the remaining tumours were classified as non-func-
tioning. A detailed clinical and family history of each patient was
taken to eliminate the possibility of MEN 1 or familial isolated
hyperparathyroidism.
Isolation of DNA
Constitutional DNA was isolated from lymphoblastoid cell lines
(LCLs) using a method based on that of Miller et al (1986). DNA
was isolated from frozen tumour tissue as follows: surrounding
stromal tissue was removed from the specimen with a scalpel, then
tumorous material was homogenized in lysis buffer (10 mM Tris-
HCl, 2 mM EDTA, 400 mM NaCl) using an omni-mixer (DuPont
Sorvall), and DNA was isolated using the same protocol as for
LCLs.
SSCP analysis
Tumour samples were screened for the presence of somatic muta-
tions using single strand conformation polymorphism (SSCP)
analysis (Orita et al, 1989). Exons 3–10 of the MEN1 gene were
amplified by PCR using approximately 50 ng of tumour DNA
from each patient in a 10 µ l reaction volume as follows: 10 mM
Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, 200 µ M dNTPs
(Promega), 10 pmol each primer (listed in Lemmens et al, 1997),
5% DMSO, 0.75 U AmpliTaq Gold DNA polymerase (PE
Biosystems) and 1 µ Ci [α -32P]-dCTP (Amersham). Samples were
cycled in an Omnigene (Hybaid) thermal cycler as follows: 95° C
for 12 minutes, followed by 35 cycles of 95° C for 1 minute, 62° C
(64° C for gene fragment 10.1) for 1 minute and 72° C for 90
seconds. 20 µ l of loading dye were added to each PCR product,
and 2.5 µ l of each sample were electrophoresed under two
different gel conditions: (i) 0.6   MDE gel solution (FMC
bioproducts) at 5 W for 16 hours, and (ii) 0.5   MDE containing
10% glycerol at 7 W for 16 hours. Gels were exposed to X-ray
film (Fuji) overnight. Autoradiographs were examined for samples
showing shifts in migration patterns compared with known wild
type controls.
LOH analysis
Approximately 50 ng of LCL DNA and corresponding tumour
DNA from each patient were amplified by PCR using the
following microsatellite markers.
D11S4936, D11S4939, D11S4940, D11S449
These markers were amplified as described by Manickam et al
(1997), using 0.75 U of AmpliTaq Gold DNA polymerase. Primer
sequences for D11S449 were obtained from Debelenko et al
(1997d).
PYGM (CAGAn repeat)
PCR reactions were prepared as described for SSCP analysis and
cycled as follows: 95° C for 12 minutes, followed by 25 cycles of
95° C for 1 minute, 62° C for 1 minute and 72° C for 2 minutes.
Primer sequences were obtained from Iwasaki et al (1992).
D11S480, D11S913
PCR reactions were prepared as described for SSCP analysis and
cycled as follows: 95° C for 12 minutes, followed by 35 cycles of
95° C for 1 minute, 58° C (53° C for D11S913) for 1 minute and
72° C for 90 seconds. Primer information was obtained from
Debelenko et al (1997d).
Twenty µ l of loading dye were added to PCR products and
3.5 µ l of each sample were electrophoresed through a 6% dena-
turing polyacrylamide (19:1) gel containing 7 M urea at 1500 V
for 3–6 hours, depending on product size. Gels were exposed to
autoradiographic film (Fuji) for 1 hour overnight. Heterozygous
samples were examined by eye for a reduced intensity of one allele
in the tumour DNA lane, compared with the adjacent normal DNA
lane. Constitutionally homozygous samples were scored as
non-informative.
DNA sequence analysis
Approximately 50 ng of DNA to be analysed were amplified by
PCR as described for SSCP, but in a 50 µ l reaction volume without
radiolabel. Exon 2 of the MEN1 gene was amplified using the
following primers: (forward) 5′ -GTGAGCAGAGGCTGAA-
GAGG-3′ and (reverse) 5′ -ATAACACCTGCCGAACCTCAC-3′
with an annealing temperature of 64° C. 1 M betaine was included
in this reaction instead of DMSO. The following primers were
used for PCR of exon 3: 5′ -AGGTTGGGTCACAGGCTTG-3′
(forward) and 5′ -CTATGTGGGTGGTGATGGG-3′ (reverse) and
annealed at 58° C. PCR products were purified by agarose gel elec-
trophoresis and bands of the correct size were excised. DNA was
isolated from the agarose using a QIAquick gel extraction kit
(QIAGEN) as per the manufacturer’s instructions. 200–300 ng of
purified PCR product was sequenced using Big Dye dye termi-
nator reaction premix (PE Biosystems) as per the manufacturer’s
instructions in a half reaction volume. Primers used were the same
as for PCR. Cycling reactions were performed on a Selby TS-
MP96 thermal cycler. Sequences were determined using an
ABI377 automated sequencer, and sequence traces were manually
analysed for the presence of heterozygous peaks. In addition,
sequence traces were aligned to the MEN1 gene sequence
(GenBank U93237) using Mac Vector 4.1.1 (Kodak) software to
identify possible homozygous base changes.
RESULTS
A total of 8 sporadic pituitary tumours, 3 pancreatic tumours, 14
primary parathyroid lesions and 8 secondary parathyroid lesions
were examined for the presence of allelic deletions of the MEN1
locus on chromosome 11q13 and mutations of the MEN1 gene.
Clinical details of these tumours are given in Tables 1 and 2.
LOH of microsatellite markers located within an approximately
2.8 megabase (Mb) region flanking the MEN1 locus, between
D11S480 and D11S1337 (Manickam et al, 1997), was detected in
4/33 sporadic endocrine lesions – 1 glucagonoma and 3 primary
parathyroid lesions (Tables 1 and 2). Figure 1 shows characteristic
LOH patterns detected for each of the 7 markers used.
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of somatic mutations in all 33 sporadic tumours using SSCP.
Band-shifts (Fig. 2) were detected in the glucagonoma sample and
in one of the parathyroid lesions also showing LOH. Sequencing
of the relevant exons resulted in the identification of 2 missense
mutations, in exons 3 and 7 respectively. Patient 40653–001 was
found to have a 4387A>T base change, resulting in a protein
change of E179V, and the mutation in patient 40769–001 was
6071C>T (P320L). The P320L mutation has been previously iden-
tified in a Japanese MEN 1 patient (Tanaka et al, 1997), but the
E179V mutation is novel. The corresponding constitutional DNA
from these patients was found to be wild type, thus confirming that
the mutations occurred somatically. Sequence traces demon-
strating this are shown in Figure 3.
In addition to SSCP analysis of the other two parathyroid
adenomas displaying LOH, the entire coding region of the MEN1
gene was sequenced in these samples. No mutation was detected in
DNA from these tumours.
During the process of mutation analysis, a number of sequence
polymorphisms were detected. These include the commonly-
reported D418D and R171Q variants, as well as an A342A poly-
morphism (6138G>A), which we report here for the first time.
This polymorphism was only identified once out of approximately
100 MEN 1 patient samples and sporadic endocrine tumour
sample analysed, and was found in the tumour sample with the
P320L mutation. For these reasons, and also because the protein
sequence is not altered, this base change was not deemed to be a
somatic mutation.
Sporadic mutations of the MEN1 gene 1005
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Table 1 Clinical features and LOH analysis of 22 sporadic parathyroid lesions
Patient Age at 1° or Glands Clinical details D11S480 PYGM D11S4940 D11S4939 D11S4936 D11S449 D11S913
ID No. surgery 2° involved
(years)
40651 82 1° R sup adenoma    –– –   –
40652 59 1° R sup adenoma       –– –      
40654 82 1° L inf adenoma     –     
40673 44 1° 1 gland adenoma –    –– –      
40703 24 1° L inf adenoma       –          –
40712 24 1° R sup adenoma –          ––   
40732 49 1° L sup, R sup hyperplasia       –            
40734 47 1° L sup hyperplasia    –– – – –
40744 36 1° R inf adenoma    –    –         
40767 50 1° R sup adenoma          ––– –
40769 49 1° R inf, R sup adenoma –          –
40776 67 1° R inf adenoma; diabetes,                     
mild renal impairment
40795 82 1° R inf adenoma –       –––   
70006 1°          –       –
40714 44 2° all 4 renal transplant –––            
40715 64 2° all 4 renal transplant       –            
40718 48 2° all 4 renal transplant          ––      
40719 36 2° all 4 renal transplant    ––    –    –
40723 44 2° all 4 renal transplant       –            
40724 53 2° all 4 renal transplant                     
40726 62 2° all 4 diabetes, nephropathy                     
40808 2° all 4 renal failure             –    –
1° = primary hyperparathyroidism; 2° = secondary hyperparathyroidism; L = left; R = right; sup = superior; inf = inferior;    = no LOH;   = LOH; – = not
informative; blanks indicate information unavailable
Table 2 Clinical features and LOH analysis of sporadic pancreatic and anterior pituitary lesions
Patient Age at Tumour Hormone Symptoms D11S480 PYGM D11S4940 D11S4939 D11S4936 D11S449 D11S913
ID No. surgery type over-secreted
(years)
40653 70 pancreas gluc     –– –  
40711 82 pancreas ins hypoglycaemia                   –
41042 51 pancreas ins             –– –
40716 57 pituitary NF             –      
40717 59 pituitary NF hypopituitarism –    –––    –
40741 76 pituitary NF –––    –      
40768 50 pituitary pro             –      
40773 31 pituitary pro galactorrhoea, headaches       –    –    –
40785 39 pituitary GH acromegaly, headaches          ––    –
40788 27 pituitary NF                     
40819 pituitary GH    –    –      
gluc = glucagon; ins = insulin; GH = growth hormone; pro = prolactin; NF = clinically non-functioning;    = no LOH;   = LOH; – = not informative; blanks indicate
information unavailableDISCUSSION
The role of the MEN1 gene in sporadic endocrine tumorigenesis is
well established. To further analyse the extent to which this gene is
involved in the development of such tumours, we analysed 14
primary and 8 secondary parathyroid lesions, 3 pancreatic tumours
and 8 pituitary tumours for the presence of allelic deletions and
somatic mutations.
Of the 14 primary parathyroid lesions analysed, 3 (21%)
showed LOH at the MEN1 locus, and 1 (7%) of these carried a
somatic mutation. Previous studies have found the rate of allelic
deletion of the MEN1 locus in this type of tumour to be similar, at
approximately 30% (Carling et al, 1998; Farnebo et al, 1998).
Moreover, MEN1 gene mutations have previously been identified
in 9–21% of parathyroid lesions studied (Heppner et al, 1997;
Shan et al, 1998), comparable with our results. Parathyroid tumori-
genesis can occur by other mechanisms such as cyclin D1 overex-
pression (Rosenberg et al, 1991), however this possibility was not
assessed in this study. Of the 8 secondary parathyroid lesions
examined, no LOH or MEN1 gene mutations were detected. This
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D11S480
D11S4940
D11S4936 D11S449 D11S913
PYGM
Figure 1 Representative patterns of LOH detected for 6 of the 7
microsatellite markers analysed. For each marker, lane 1 is LCL DNA, and
lane 2 is corresponding tumour DNA. The PYGM tumour lane also shows
possible microsatellite instability
A B
C
D
Figure 2 Autoradiographs showing SSCP band-shifts for 2 somatic
mutations. (A) Migration pattern for exon 3.1 in 0.6 X MDE. Lane 1 is wild
type, lane 2 is the E179V missense mutation, and lane 3 contains a sample
carrying a R171Q polymorphism. (B) Migration pattern for exon 3.1 in a gel
containing 10% glycerol, loaded as per. A. (C) Exon 7 PCR products in 0.6 X
MDE. Lanes 1 and 3 are wild type, and lane 2 contains the P320L missense
mutation. (D) The same samples as in C, in a gel containing 10% glycerol.
A B
C D
Figure 3 Sequence traces showing somatic MEN1 gene mutations
identified. (A) A portion of exon 3 sequence in LCL and (B) same sequence
in the corresponding glucagonoma showing A–T transversion responsible for
E179V. (C) Portion of exon 7 complementary strand from LCL and (D) in
corresponding parathyroid adenoma showing G–A (reverse strand) transition
resulting in a P320L substitution.
D11S4936 D11S449 D11S913result supports those of previous studies (Farnebo et al, 1997a,b),
suggesting that hyperparathyroidism arising as a consequence of
renal failure occurs following some other genetic trigger.
Of the three pancreatic adenomas analysed, a glucagonoma was
found to have both LOH and a somatic MEN1 mutation. The low
number of such lesions precludes statistical comparisons between
this and other studies. No LOH or mutations were detected in any
of the pituitary tumour samples. Once again, a relatively small
number of samples was analysed, but previous studies reflect a
similar finding, wherein 10% or fewer pituitary tumours show
involvement of the MEN1 locus (Zhuang et al, 1997b; Prezant et
al, 1998). Numerous other loci have been implicated in pituitary
tumorigenesis, including the gsp oncogene (Landis et al, 1989),
and the TP53 (Bates et al, 1997) and CDKN2A (Woloschak et al,
1996) tumour suppressor genes.
In the four tumours with LOH, allelic loss was detected across
the entire region studied. This confirms the findings of others, in
which deletions of the wild type allele in sporadic endocrine
tumours are generally large and cover many kilobases (Heppner et
al, 1997). Since some of the tumours analysed were uninformative
at the microsatellite markers closest to the MEN1 gene (e.g.
PYGM and D11S4940), it is formally possible that some small
allelic deletions might have gone undetected. However, because
large deletions are usually observed, this is unlikely. It is possible
that the two tumours carrying LOH at the MEN1 locus without
detectable MEN1 gene mutations have the second MEN1 allele
inactivated by some other mechanism such as transcriptional
silencing by promoter methylation, although we were not able to
test this in this study, as RNA was not available from these
tumours.
In summary, we have found LOH at the MEN1 locus in 3
sporadic primary parathyroid lesions and in 1 sporadic
glucagonoma. Somatic mutations in the MEN1 gene were identi-
fied in one of these parathyroid lesions and in the glucagonoma.
This supports previous findings that the MEN1 gene is involved in
the development of a subset of sporadic MEN 1-type endocrine
lesions. Also confirmed are previous results suggesting that the
development of secondary hyperparathyroidism occurs by some
other genetic mechanism, rather than mutation of the MEN1 gene.
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